36 results about "CXCL10" patented technology

Provided herein are methods and immune biomarkers that identify progression and treatment options for multiple sclerosis (MS). Also provided are materials and methods for the prognosis, staging, and monitoring of MS in a sample and include methods of determining a subject as being at risk of developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3 in cerebrospinal fluid (CSF) in the subject; and administering a pharmaceutically effective amount of a treatment (e.g., tolebrutinib and potentially one or more additional therapies, such as an anti-CD20 therapy) to the subject.

The invention belongs to the technical field of biological medicine, and particularly relates to application of cynarin as a cGAS-STING signal channel inhibitor in preparation of anti-inflammatory drugs. It is found for the first time that cynarin can inhibit phosphorylation of STING and translocation of STING by influencing the stability of STING spatial conformation, so that channel downstream protein activation is inhibited, nuclear translocation of IRF3 is hindered, expression of a series of interferon-induced related genes such as IFN-beta, CXCL10 and ISG15 is inhibited, finally secretion of IFN-beta can be hindered, cGAS-STING inflammatory response can be inhibited by targeting STING, and the application of cynarin in inhibiting cGAS-STING inflammatory response is achieved. A new thought and a new means are provided for developing an auxiliary treatment method aiming at STING related inflammations.

The invention belongs to the technical field of medicine, particularly relates to application of isodan-leaf emodin in preparation of a CXCL10 inhibitor, and particularly relates to application of the isodan-leaf emodin in treatment of sepsis lung injury, and by establishing a sepsis lung injury model induced by cecum ligation puncture (CLP), the application of the isodan-leaf emodin in preparation of the CXCL10 inhibitor is established. It is proved that the polyphenol monomer drug isodan leaf emodin can significantly improve lung tissue pathological damage, reduce the level of inflammatory factors in lung tissue, inhibit oxidative stress reaction and improve the survival rate of a CLP model. Experiments show that the isodan leaf emodin with the dosage of 25 mg / kg can relieve pulmonary edema and inflammatory response by inhibiting secretion of CXCL10, and a new scheme is provided for treatment of sepsis-related lung injury.

The invention relates to a prediction model for judging prognosis and immunotherapy response of ovarian cancer based on machine learning. The prediction model comprises the following steps: determining gene expression quantities of eight markers, namely ANGPTL4, AREG, CXCL10, FANCB, GMPR, IGF1, LYG1 and WNK 1. The invention also provides a gene combination kit for predicting the prognosis and immunotherapy response of the ovarian cancer and application of the gene combination kit. The invention provides a prediction model aiming at ovarian cancer, which is used for judging the prognosis of a patient, can assist in guiding immunotherapy and prognosis judgment, and helps to realize personalized treatment aiming at a specific patient. Experiments and tumor big data support the prognosis model, the prognosis and immunotherapy response of a patient can be effectively predicted by integrating various biological and clinical data, powerful support can be provided for individualized treatment, a treatment scheme can be optimized, and the survival rate and life quality of the patient can be improved.

The assay system allows for the study of cell migration through tissue-associated extracellular matrix under chemokine gradients within a modular assay platform. Using this assay system, activated CD3+ T cells migrating towards chemokines (CXCL10 and CXCL12) and chemokine mimetics (CXCR3 agonists) were detected, quantified, and studied. This assay system facilitates drug discovery and the study of the microenvironment, stimuli, and responding cells.

An assay system permits study of cell migration through tissue-relevant extracellular matrices under a chemokine gradient within a modular assay platform. Activated CD3+ T-cells were detected, quantified, and studied as they migrated towards chemokines (CXCL10 and CXCL12) and chemokine mimetics (CXCR3 agonist) using the assay system. Discovery of drugs, and the study of microenvironments, stimuli, and responding cells are facilitated by the assay system.

The invention discloses application of a targeted Nup85 inhibitor in preparation of a medicine for preventing or treating hepatocellular carcinoma, and relates to the technical field of biological medicine and tumor immunotherapy. The invention provides an application of a targeted Nup85 inhibitor in preparation of a medicine for preventing or treating hepatocellular carcinoma. The inhibitor prevents and / or treats hepatocellular carcinoma by enhancing CD8 + T cell functions, enhancement of the CD8 + T cell functions is realized by regulating STAT1 / CCL5 / CXCL10 pathways, and Nup85 reduces expression of CCL5 and CXCL10 by inhibiting nuclear translocation of phosphorylated STAT1, so that infiltration and activation of CD8 + T cells are inhibited. The invention discloses an immune escape mechanism that Nup85 inhibits CD8 + T cell infiltration by inhibiting p-STAT1 nuclear translocation and down-regulating CCL5 / CXCL10 expression in liver cancer for the first time, provides a new liver cancer immunotherapy target, and broadens the application of nucleopore protein in tumor immunotherapy; the target Nup85 inhibitor can be obtained through a conventional means, a new clinical application direction of the target Nup85 inhibitor is defined, and the target Nup85 inhibitor has good clinical transformation and development prospects.

The present invention provides: an oncolytic virus such as a conditionally replicating adenovirus carrying the CXCL10 gene; the oncolytic virus additionally carrying the IL-2 gene and / or the GM-CSF gene on the same viral genome; a combination of the oncolytic virus and a separate oncolytic virus carrying the IL-2 gene and / or the GM-CSF gene; and a cancer treatment agent comprising any of the aforementioned oncolytic viruses or a combination thereof as an active ingredient.

An assay system permits study of cell migration through tissue-relevant extracellular matrices under a chemokine gradient within a modular assay platform. Activated CD3+ T-cells were detected, quantified, and studied as they migrated towards chemokines (CXCL10 and CXCL12) and chemokine mimetics (CXCR3 agonist) using the assay system. Discovery of drugs, and the study of microenvironments, stimuli, and responding cells are facilitated by the assay system.

The present invention relates to C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and their use in methods of detecting and / or diagnosing a condition in a subject, including determining the level of CXCL10 in a subject. Specific antibodies that bind total CXCL10 (full length, N-terminally truncated and citrullinated) and antibodies that bind active CXCL10 (full length) are used to measure the level of total CXCL10 and active CXCL10 in ovarian cancer patient samples. The calculated ratio between active CXCL10 and total CXCL10 is lower in patients with malignant disease compared to patients with benign tumors or healthy individuals, and this calculated ratio is the basis for methods of diagnosing malignant disease, monitoring tumor burden and disease progression.

The invention provides an application of a MAT2A inhibitor in preparation of a medicine for preventing and / or treating inflammation. A cell experiment result shows that the MAT2A inhibitor has a remarkable inhibition effect on an inflammatory cell model after administration, and mRNA expression levels of various inflammatory factors TNF-alpha, IFN-gamma, IL-1beta, IL-6, IL-12a and CXCL10 in cells are remarkably reduced; the invention provides a new direction for treating inflammatory diseases.

The invention relates to an application of a cytokine CXCL10 in depression and / or anxiety disorder. Specifically, the inventor verifies that the cytokine CXCL10 can effectively treat depression and / or anxiety disorders.

The invention relates to the technical field of biological medicine, and discloses a medicine composition for promoting anti-tumor immunity and application of the medicine composition in preparation of medicine for treating tumors, the medicine composition comprises small molecules and a PD-1 antibody, and the small molecules have the following structure: # imgabs0 #. The micromolecule obtained by the invention can target REXO4 enzyme and inhibit the enzyme activity of the REXO4 digestion R-loop structure, so that the increase of the R-loop structure of tumor cells is promoted, and the purposes of promoting infiltration of anti-tumor immune cells and inhibiting tumor growth are achieved. The small molecule can promote generation of I-type interferon related chemotactic factors Cxcl10 of tumor cells, so that recruitment of anti-tumor related immune cells is caused, an immune checkpoint inhibitor therapy is enhanced, and the aim of killing the tumor cells is achieved.

The application belongs to the technical field of biological medicine, and particularly relates to the use of SH2 domain-containing protein tyrosine phosphatase 1 (SHP1) in the preparation of a drug for treating chronic pain, in particular to the use of SHP1 in the preparation of a drug for treating chronic pain by regulating the morphology of spinal cord astrocytes, the integrity of the blood-spinal cord barrier and the STAT1-CXCL10-CXCR3 neuroimmune signal axis, and a chronic pain treatment strategy based on the signal axis. The application first discloses that SHP1 in spinal cord astrocytes directly dephosphorylates STAT1, inhibits the transcription of CXCL10 and the subsequent infiltration of T lymphocytes into the spinal cord, and discloses the core analgesic mechanism, thereby establishing SHP1 as a new target for treating chronic pain, and opening up a new way for the precise treatment of clinical chronic pain, especially neuropathic pain.

The present disclosure relates to a method for assessing the risk that a subject suffers from a malignant condition and / or detecting and / or diagnosing a malignant condition comprising determining a CXCL10 ratio of active CXLC10 to total CXCL10 in the subject; and the level of cancer antigen 125 (CA-125), human epididymis protein 4 (HE4) and interleukin 6 (IL-6) in the subject.

The invention relates to a targeted B7-H3 chimeric antigen receptor-T cell for expressing CXCL10 and application of the targeted B7-H3 chimeric antigen receptor-T cell in tumor treatment. The targeted B7-H3 chimeric antigen receptor-T cell comprises a targeted B7-H3 chimeric antigen receptor, a chemotactic factor CXCL10 and application of the targeted B7-H3 chimeric antigen receptor-T cell in tumor treatment. The chemotactic factor provided by the invention can effectively promote the effect of CAR-T cell immunotherapy.

A MASH biomarker composition and an application thereof is provided, the biomarker composition including a protein marker and / or clinical biochemical marker for the diagnosis of MASLD and / or MASH, the protein marker being selected from CXCL10, CK-18, P62 / SQSTM1, CA3, SQLE, Pro-C3 or one or more of FGF21; the clinical biochemical marker is selected from one or more of BMI, HDL-C, HbA1c, ALT, AST, LDL-C, TG, TC, ALP, or PLT. Biomarker compositions were established by logistic regression and artificial intelligence methods as diagnostic markers for the diagnosis of MASLD and MASH with high sensitivity, specificity, positive predictive value, and negative predictive value in the diagnosis of MASH, independent of age, gender, or metabolic status.

Provided herein are methods and immune biomarkers for identifying multiple sclerosis (MS) progression and treatment options. Materials and methods for prognosing, staging, and monitoring MS in a sample are also provided, including methods for determining a subject as at risk for developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3, in the cerebrospinal fluid (CSF) of a subject, and administering a pharmaceutically effective amount of a therapy (e.g., trebrutinib and potentially one or more additional therapies, e.g., an anti-CD20 therapy) to the subject.

To provide markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.SOLUTION: A method of identifying a mammalian subject with multiple sclerosis (MS) or at risk of developing MS, comprising: measuring an expression level of at least one gene selected from the group consisting of TIMP1, LRG1, CXCL1, CXCL5, CXCL10, IL-8, NFκBIZ, YKL40, and G-CSF in a biological sample taken from the subject, wherein an increased level of expression compared to a control indicates that the subject has MS or is at risk of developing MS.SELECTED DRAWING: None

Provided herein are methods and immune biomarkers for identifying progression and therapeutic selection of multiple sclerosis (MS). Also provided are materials and methods for prognosis, staging, and monitoring of MS in a sample, and including methods of determining that a subject is at risk of developing MS. The method comprises detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3, in the cerebrospinal fluid (CSF) of the subject; and administering to the subject a pharmaceutically effective amount of a treatment (e.g., tobutinib and potentially one or more additional therapies, such as an anti-CD20 therapy).

Provided are an engineered immune cell expressing CXCL10 and IL15 and the use thereof. The immune cell can further express a chimeric antigen receptor or a T cell receptor. The engineered immune cell can enhance the recruitment and accumulation of immune cells, enhance the killing efficiency of immune cells on target cells, and enhance the treatment effect of immune cells on tumors, such as solid tumors.

The invention provides a system for identifying whether a person is in an active tuberculosis infection state or not from gene expression of peripheral blood and application of the system, and the system is used for simultaneously detecting expression levels of human FCGR1A gene, FCGR1B gene, GBP5 gene, GBP6 gene, CXCL10 gene and KLF2 gene so as to determine whether the person is in the active tuberculosis infection state or not. The sensitivity of combined detection of the six genes is 91.18%, the specificity reaches 86.84%, the target requirement for terminating tuberculosis in 2035 published by the United National Health Organization is met, and TB high-risk groups can be screened out by the method and then diagnosed by a diagnosis method.

The invention provides application of a PD-1 inhibitor to preparation of a medicine for treating prostatic cancer with TP53 gene mutation, and relates to the technical field of medicine. The medicine comprises a therapeutically effective amount of the PD-1 inhibitor and a pharmaceutically acceptable carrier auxiliary component thereof. The PD-1 inhibitor and Mutp53 are related to epithelial lineage, metabolic reprogramming and recombination of CAF and immune cell population, so that the improvement of tumor immunity accessibility is promoted together. In a comprehensive view, the discovery reveals a direct mechanism relation among TP53 high-frequency mutation, Cxcl10 signal transduction and ICB treatment sensitivity, and a new biological insight and a potential strategy are provided for layering and combined treatment of patients suffering from CRPC.

The present invention relates to the use of cytokine CXCL10 in depression and / or anxiety disorders.

The invention discloses a group of molecular markers for pancreatic ductal adenocarcinoma immunohistochemical typing and application thereof. The molecular marker disclosed by the invention comprises HLA-1 (Human Leukocyte Antigen) and CXCL10 (CXCL10). Based on the clinical test result of the first application of an OPL scheme in the advanced PDAC patient and the contained multi-omics data set at present, the immunohistochemical molecule combination for predicting the treatment reaction is screened out, and implementation and verification are carried out in a pancreatic duct adenocarcinoma puncture sample before treatment; the actual treatment response of the patient is highly consistent with the prediction result of immunohistochemistry, which proves that the immunohistochemistry typing has prompting significance for the prognosis of the patient. According to the method, the defects that when disease typing and curative effect prediction are carried out through expression profile sequencing, the technology is complex, the price is high, time is consumed, and the method is difficult to apply clinically are overcome, and a basis is provided for precise treatment of PDAC.

The present application provides a system for identifying whether a person is in an active tuberculosis infection state from gene expression of peripheral blood and application thereof, the system is used for simultaneously detecting expression levels of FCGR1A gene, FCGR1B gene, GBP5 gene, GBP6 gene, CXCL10 gene and KLF2 gene, so as to determine whether the person is in an active tuberculosis infection state. The sensitivity of the 6-gene combined detection of the present application is 91.18%, and the specificity reaches 86.84%, which meets the requirements of the goal of ending tuberculosis by 2035 published by the World Health Organization, and the method of the present application can screen out high-risk TB population, and then use a diagnosis method for diagnosis.

Provided are peptides, modified peptides, fragments thereof, conjugates thereof, and polymers thereof that have antibacterial activity, including against multidrug-resistant bacteria. In some embodiments, the peptides include amino acid sequences as set forth in any of SEQ ID NOs: 2-151, modified peptides, fragments, and conjugates thereof, and any combination thereof. The peptides, modified peptides, fragments, and conjugates can be polymer-functionalized, encapsulated in a particle, embedded in and / or on a solid support, impregnated in a dressing, and / or is formulated for use in a nebulizer, for topical administration, and / or for systemic administration. Also provided are medical devices having an antibacterial agent embedded in and / or associated with a support layer, and methods for inhibiting growth of and / or killing bacteria, for treating or preventing community and / or nosocomial infections, for treating bacterial infections present in wounds, for treating pulmonary infections, for treating or preventing systemic bacterial infections, and for combination therapies with conventional antibiotics.

To provide a biomarker and a method for predicting the phases of inflammatory exacerbation and remission in autoinflammatory diseases.SOLUTION: A prediction method includes the step for measuring, as indicators, the quantity of at least one protein selected from the group consisting of IL-1β protein and ASC protein in a biological sample and / or the expression level of at least one gene selected from the group consisting of ASC, MASCRNA, DDT, C3, CD99, RNA28SN5, RNA28SN4, RNA28SN2, RNA28SN3, RNA28SN1, RN7SL1, EEF1A1, MIR922, MIR4775, SNORA5C, SNORD143, SNORD4B, MIR612, MIR6502, DDAH2, CXCL10, RNVU1-3, MIR5001, LOC107984935, MIR6721, RNVU1-14, MIR760, and SNORD19B.SELECTED DRAWING: Figure 1

The present invention relates to a method for determining a transcriptome score (TScore) suitable for assessing the risk of an undesirable clinical outcome of a patient in a clinical environment from an assay sample or population of assay samples previously extracted from the patient, the method comprising, among other steps, determining a transcriptome score (TScore) suitable for assessing the risk of an undesirable clinical outcome of the patient, gene expression values of at least two different genes selected from a predetermined set of genes are measured for a patient sample or a population of samples previously obtained from the patient, and a transcriptome score is determined, where the genes are assigned or not assigned scores. The method may be computer implemented. The genes of the predetermined set of genes may be at least two genes selected from the group consisting of ADGRE3, ARL14EP, BPGM, C3AR1, CCNB1IP1, CD177, CD274, CD3D, CD74, CIITA, CTLA4, CX3CR1, GNLY, IFNgamma, IL10, IL1R2, IL1RN, IL7R, IP10 / CXCL10, MDC1, OAS2, S100A9, TAP2, TDRD9, TNF, and ZAP70. The method may be performed on an assay biological sample extracted from a patient who has been treated in a resuscitation department, an intensive care unit, or a continued care unit. The invention also relates to a method of classifying samples previously taken from a patient as a group reflecting the risk of an undesirable clinical outcome in a clinical environment, or a method of identifying a patient at risk of an undesirable clinical outcome in a clinical environment, and an in vitro or ex vivo method of screening for whether a drug has the ability to alleviate an undesirable clinical outcome in a patient. The invention also relates to a computer device for carrying out the invention, and to the use of a kit for carrying out the method of the invention.